🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jilin City
Clinical trial register · China

Clinical Trials in Jilin City, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Xi'an Xintong Pharmaceutical Research Co.,Ltd.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2 Beijing Anzhen Hospital2 DualityBio Inc.2 Peking Union Medical College Hospital2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Jilin City

36 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
NCT07816237Paroxysmal Nocturnal Hemoglobinuria, PNH
DrugsVSA012·Eculizumab
Bisirna Therapeutics (Suzhou) Co., Ltd.
Phase 3
70
Beijing, Jilin City, Quanzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2026-10-29
Not yet open
Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults
NCT07792681Migraine, With or Without Aura
Brise Pharmaceuticals Co., Ltd.
Phase 2/3
2,079
Shanxi, Inner Mongolia, Beijing, Anhui, Hebei, Jilin City, Hunan, Chongqing
2026-09-15
Recruiting
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
NCT07776522Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
DrugAflibercept
West China Hospital
Phase 2
50
Beijing, Jilin City, Chongqing, Shantou, Zhejiang, Harbin, Zhengzhou, Wuhan
2026-08-31
Recruiting
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
NCT07697586NSCLC
DrugsSKB118·Sacituzumab tirumotecan
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
206
Jilin City, Shanghai
2026-08-07
Not yet open
AI-assisted Rare Disease Diagnosis
NCT07650799Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
1,056
Beijing, Cangzhou, Changchun, Dongguan, Foshan, Guiyang, Jilin City, Kunming
2026-08-01
Recruiting
Study of AHB-171 in Chronic Hepatitis B Participants
NCT07630727Hepatitis B, Chronic (CHB)
DrugAHB-171
Ausper Biopharma Co., Ltd.
Phase 2
138
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Changzhou, Jilin City
2026-06-24
Not yet open
Artificial Intelligence for Rare Disease Diagnosis
NCT07625436Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
150
Beijing, Cangzhou, Changchun, Dongguan, Foshan, Guiyang, Jilin City, Kunming
2026-06-20
Recruiting
A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.
NCT07593027Pulmonary Arterial Hypertension PAH
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase 1/2
120
Beijing, Jilin City, Fuzhou, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2026-04-30
Not yet open
A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.
NCT07407634Non-Alcoholic Fatty Liver Disease
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Phase EARLY_PHASE1
94
Jilin City
2026-03-25
Recruiting
Digital Remote Management Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction: a Multicentre, Randomised, Controlled Trial (DigiCare-HFrEF)
NCT07352891Heart Failure With Reduced Ejection Fraction
Beijing Anzhen Hospital
Not applicable
252
Beijing, Dalian, Jilin City, Nanchang, Shanghai
2026-02-26
Not yet open
Dexamethasone Regimens for BPD Prevention in Preterm Infants
NCT07052201Infant, Premature, Bronchopulmonary Dysplasia (BPD)
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
970
Hangzhou, Chengdu, Chongqing, Guangdong, Guangxi, Guiyang, Guizhou, Jilin City
2026-02-01
Not yet open
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
NCT07365371Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
DrugAflibercept Intravitreous
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4
174
Beijing, Foshan, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jilin City
2026-01-01
Not yet open
Cough Flow as a Criterion Decannulation Threshold in Prolonged Tracheostomy Patients
NCT07317791Tracheostomy
Hongying Jiang, MD
Not applicable
500
Beijing, Hunan, Guangxi, Jilin City, Henan
2026-01-01
Not yet open
Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD)
NCT07332494Coronary Heart Disease, Percutaneous Coronary Intervention
Beijing Anzhen Hospital
Not applicable
792
Beijing, Dalian, Jilin City
2026-01
Recruiting
68Ga-BCMA PET/CT in Multiple Myeloma
NCT07319897Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
Peking University First Hospital
Phase 2/3
300
Beijing, Shijiazhuang, Jilin City
2025-12-25
Recruiting
SV With TTPEE Measurement Predicts Upper Airway Patency in Prolonged Tracheostomy Patients
NCT07107243Tracheostomy
Capital Medical University
Not applicable
300
Hunan, Guangxi, Beijing, Jilin City, Henan
2025-10-01
Recruiting
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
NCT07137910Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou
2025-09-04
Recruiting
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
NCT06924606Advanced NSCLC
DrugsJS004·JS207·Paclitaxel
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
66
Beijing, Jilin City, Hunan, Sichuan, Chongqing, Guangdong, Heilongjiang, Anyang
2025-07-15
Active, closed
A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B
NCT07203118Chronic Hepatitis B
DrugTAF
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Phase 2/3
1,444
Jilin City
2025-07-01
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Not yet open
Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression
NCT06920706Post-stroke Depression, Remote Ischemic Conditioning
Xuanwu Hospital, Beijing
Not applicable
240
Tongren, Baoding, Jilin City, Jincheng, Beijing
2025-04-10
Active, closed
Evaluate the Effectiveness and Safety of the OmniHeart 4.0 Percutaneous Ventricular Assist Device in Providing Hemodynamic Support for Patients Undergoing High-risk Percutaneous Coronary Intervention (PCI).
NCT07622446High-risk PCI
Shanghai Dynaheart Medtech Co., Ltd.
Not applicable
254
Jilin City, Shanghai
2024-12-30
Recruiting
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
NCT06736327Advanced Solid Tumors
DrugSKB500
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
180
Jilin City
2024-12-13
Not yet open
Phimume® Percutaneous Left Ventricular Assist System Study
NCT06639321Coronary Artery Disease
Shanghai NewMed Medical Co., Ltd.
Not applicable
250
Jilin City, Chengdu, Zhengzhou, Wuhan, Changsha, Shenyang
2024-10-14
Recruiting
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
NCT06496048Relapsed Small Cell Lung Cancer
DrugsLurbinectedin·Topotecan·Irinotecan
Luye Pharma Group Ltd.
Phase 3
180
Jilin City
2024-09-14
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795Solid Tumor, Adult
DualityBio Inc.
Phase 1/2
360
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang
2024-09-03
Recruiting
A Trial of SHR-4849 in Advanced Solid Tumors
NCT06443489Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
80
Jilin City
2024-06-26
Recruiting
the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children
NCT05911893Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition
Children's Hospital of Chongqing Medical University
Not applicable
200
Hefei, Beijing, Jilin City, Chongqing, Guangzhou, Guiyang, Changsha, Nanjing
2024-06-17
Active, closed
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485Advanced Solid Tumor
DrugsValemetostat Tosylate·Dato-DXd·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Active, closed
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
NCT06265428HER2-positive Breast Cancer
DrugsDB-1303/BNT323·Trastuzumab emtansine
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Active, closed
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
DrugAficamten
Cytokinetics
Phase 3
500
Guangzhou, Beijing, Jilin City, Nanjin, Shanghai, Shenyang, Wuhan, Xi'an
2023-08-31
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370Coronary Artery Disease, Heart Failure Systolic
Sunnybrook Health Sciences Centre
Not applicable
754
Jilin City, Shanghai
2023-06-22
Recruiting
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
NCT05504278Advanced Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
144
Jilin City
2022-09-20
Active, closed
TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration
NCT05461339Neovascular Age-related Macular Degeneration
BioDlink Biopharm Co., Ltd.
Phase 3
488
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen
2022-06-28
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
NCT05171816Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone acetate·Olaparib
AstraZeneca
Phase 3
110
Beijing, Chongqing, Guangzhou, Guizhou, Henan, Hubei, Hunan, Jilin City
2021-06-24
Active, closed
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
NCT03447938Coronary Artery Disease
Ottawa Heart Institute Research Corporation
Not applicable
176
Jilin City
2018-09-01
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/jilin-city

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Jilin City.

How many clinical trials are recruiting in Jilin City?

17 of the 36 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 11 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jilin City), 36 studies
PhaseStudiesRecruitingShare
Not applicable13536.1%
Phase 37119.4%
Phase 25513.9%
Phase 14311.1%
Phase 2/3318.3%
Phase 1/2225.6%
Phase 4102.8%
Phase EARLY_PHASE1102.8%

Most active sponsors

Lead sponsors with the most studies (Jilin City)
Lead sponsorStudiesRecruiting
Ausper Biopharma Co., Ltd.22
Beijing Anzhen Hospital21
DualityBio Inc.21
Peking Union Medical College Hospital20
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.22
Xi'an Xintong Pharmaceutical Research Co.,Ltd.20
Air Force Military Medical University, China11
AstraZeneca10
BioDlink Biopharm Co., Ltd.10
Bisirna Therapeutics (Suzhou) Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.